About the Studies
These studies are designed to evaluate the safety and effectiveness of efimosfermin, an investigational injection, that is being researched to improve liver health in adults with liver scarring due to Metabolic Dysfunction-Associated Steatohepatitis (MASH), also known as fatty liver disease. Efimosfermin is an “investigational” drug because it has not been approved by the Food and Drug Administration (FDA).
The studies are randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 50% chance you will receive the study treatment and a 50% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
The duration of the studies is 5-7 years depending on which study you may qualify for, and will include a screening period, a treatment period, and a follow up period. The studies will require in-clinic visits and in some cases telephone visits. If you qualify and choose to participate, you may be compensated up to $5,000 - $7,000 for your study-related time and travel. There may also be a possibility to join an open label extension following participation where the active drug will be received. Your participation is entirely voluntary, and you can leave the study at any time.